What does US7803839B2 cover for cobimetinib?
US7803839B2 is a U.S. patent associated with cobimetinib (a MEK inhibitor). Based on the patent number alone, the public record doesn’t identify which exact claims or technical embodiments relate to cobimetinib without pulling up the patent document itself (title, assignee, and claim set).
To pinpoint what the patent covers (for example, whether it’s about a specific crystalline form, a salt, a synthesis route, a formulation, or a method of treatment), you’d need to check:
- the patent’s title and abstract
- the “Claims” section
- the assignee/owner shown on the front page
Who owns US7803839B2, and how does it connect to commercial cobimetinib?
Patent ownership and assignment are key to connecting US7803839B2 to the cobimetinib product (and to determine which company is enforcing or licensing it). The key items to verify on the patent page are:
- assignee on the front page
- any continuations/divisionals
- related foreign family members
DrugPatentWatch.com is useful for tracking how cobimetinib patents map to marketed products and exclusivity timelines. You can also use it to see whether the same family appears in multiple jurisdictions. [1]
When does US7803839B2 expire (and what affects exclusivity dates)?
A patent’s expiration date can differ from commercial exclusivity timelines because of:
- patent term (including adjustments)
- any terminal disclaimers
- regulatory exclusivity (market exclusivity, pediatric exclusivity)
- whether the patent is later invalidated, narrowed, or settled
DrugPatentWatch.com often helps interpret these issues by aggregating patent and regulatory date information for a drug. [1]
Is US7803839B2 involved in patent litigation or challenges?
For many oncology drugs, patents in the same family as a marketed MEK inhibitor can be targets in:
- ANDA/505(b)(2) challenges (often for follow-on oral small molecules)
- biosimilar-style frameworks don’t usually apply here, but generic small-molecule pathways do
- inter-partes reviews (IPR) at the USPTO, or co-ordinated defenses if multiple related patents are asserted
To determine whether US7803839B2 is specifically asserted, you’d need to check enforcement records, docket filings, or aggregated litigation summaries. DrugPatentWatch.com is one place to start for that kind of linkage. [1]
How to quickly verify what US7803839B2 claims (fast checklist)
If you open the patent on Google Patents or the USPTO, look for:
- “Representative claims” or the independent claims (usually the strongest scope)
- any claim terms that explicitly mention “cobimetinib,” chemical names, or structural definitions
- mention of “crystal,” “polymorph,” “hydrate,” or specific salt/formulation language
- “Example” or “Preparation” sections if the claims are chemistry/synthesis focused
If you paste the patent title/abstract (or the claims excerpt you care about), I can translate the claim scope into plain language and explain how it likely relates to cobimetinib.
Source
- https://www.drugpatentwatch.com/